The EVERSANA MANAGEMENT CONSULTING team provides an overview of the recent developments and shares their views on the strategic implications for manufacturers.
Manufacturers must act decisively to mitigate Most Favored Nation (MFN) exposure through global pricing strategy, stakeholder engagement, and confidential contracting.
- Develop evidence dossiers for therapeutic value and negotiation leverage
- Participate in CMS public comment periods and listening sessions
- Consider raising prices or delaying launches in OECD reference countries
- Reassess global launch sequencing to avoid anchoring U.S. prices to low-cost markets
- Explore value-based or net-price contracting to maintain access
- Engage the U.S. administration diplomatically to support trade efforts aimed at increasing OUS prices
- Work proactively with OUS governments to implement confidential pricing frameworks of net prices and reduce exposure to U.S. surveillance efforts
Complete the form below to download our full May 23, 2025 report to read more insights from our experts.
Please note that the views and perspectives shared in this report reflect the information available as of May 23, 2025.
Author
David brings 34 years of pharmaceutical, biotechnology, device, and diagnostic industry leadership experience in commercialization, market access, reimbursement, HEOR, government affairs, sales, and marketing. Currently, David co-leads the EVERSANA U.S. Pricing and Market Access…
Chad provides high-impact results for biopharmaceutical companies through strategy and pricing initiatives. His experience includes revenue-optimal pricing for rare disease therapies, market assessments informing product launch decisions and product commercialization, and payer insight research…
Andrew Ying is a Consultant with EVERSANA MANAGEMENT CONSULTING. Prior to joining EVERSANA MANAGEMENT CONSULTING, Andrew was a Life Sciences Analyst with CBPartners, where he facilitated launch plans with multi-national pharmaceutical companies for…